AMAG Pharmaceuticals (AMAG) and The Competition Head to Head Contrast
AMAG Pharmaceuticals (NASDAQ: AMAG) is one of 111 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare AMAG Pharmaceuticals to similar companies based on the strength of its risk, analyst recommendations, institutional ownership, earnings, dividends, profitability and valuation.
This table compares AMAG Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AMAG Pharmaceuticals Competitors||-3,504.06%||-46.10%||-7.77%|
This is a breakdown of current ratings for AMAG Pharmaceuticals and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AMAG Pharmaceuticals Competitors||938||3769||5982||164||2.49|
AMAG Pharmaceuticals currently has a consensus price target of $28.45, suggesting a potential upside of 39.14%. As a group, “Pharmaceuticals” companies have a potential upside of 24.49%. Given AMAG Pharmaceuticals’ higher probable upside, equities analysts clearly believe AMAG Pharmaceuticals is more favorable than its competitors.
Risk and Volatility
AMAG Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, AMAG Pharmaceuticals’ competitors have a beta of 0.86, indicating that their average share price is 14% less volatile than the S&P 500.
Insider & Institutional Ownership
43.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.8% of AMAG Pharmaceuticals shares are held by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares AMAG Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|AMAG Pharmaceuticals||$593.24 million||$237.60 million||-15.26|
|AMAG Pharmaceuticals Competitors||$7.88 billion||$2.49 billion||1.08|
AMAG Pharmaceuticals’ competitors have higher revenue and earnings than AMAG Pharmaceuticals. AMAG Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
AMAG Pharmaceuticals competitors beat AMAG Pharmaceuticals on 7 of the 12 factors compared.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.